Objective-To assess the association of circulating total bilirubin and cardiovascular disease (CVD) risk in a new prospective study and to determine whether adding information on total bilirubin values to established cardiovascular risk factors is associated with improvement in prediction of CVD risk. Approach and Results-Circulating total bilirubin levels were measured at baseline in the PREVEND (Prevention of Renal and Vascular End-stage Disease) prospective study of 7222 participants and 773 incident CVD events. Total bilirubin was log-linearly associated with CVD risk. Age-and sex-adjusted hazard ratio (95% confidence interval) for CVD per 1-SD increase in log e total bilirubin was 0.82 (0.76 to 0.88; P<0.001), which was minimally attenuated to 0.89 (0.82 to 0.96; P=0.003) after further adjustment for established risk factors. In a meta-analysis of 12 population-based prospective studies involving 9378 incident CVD cases, the pooled multivariate-adjusted relative risk (95% confidence interval) for CVD was 0.93 (0.90 to 0.97; P<0.001) per 1-SD increase in total bilirubin levels. The corresponding pooled risks for coronary heart disease and stroke were 0.95 (0.92 to 0.99; P=0.018) and 0.93 (0.88 to 0.98; P=0.006), respectively. Addition of information on total bilirubin to a CVD risk prediction model containing established risk factors was associated with a C-index change of 0.0013 (−0.0004 to 0.0029; P=0.13).
S erum circulating total bilirubin, a breakdown product of normal heme catabolism, 1 is useful for assessing liver function and has been widely used as a marker of cholestasis. 2 Several prospective population-based cohort studies have assessed the associations between total bilirubin levels and risk of cardiovascular disease (CVD) and have generally suggested inverse associations. [3] [4] [5] [6] [7] [8] Nonetheless, uncertainties remain about the shape, magnitude, and consistency of the association because majority of the earlier reports were insufficiently powerful to address these aspects. Furthermore, some of these studies were conducted in populations at high vascular risk 6 or with coexisting morbidities, such as Gilbert syndrome 9 or chronic kidney disease. 10 Among the studies that were based on general populations, some reported inverse associations, 3, 5 whereas others showed modestly positive or null associations. 11, 12 An earlier meta-analysis of 11 studies reported an inverse relationship between total bilirubin and atherosclerotic disease and suggested a linear dose-response relationship. 13 There were, however, several limitations to the review. First, results on a variety of atherosclerotic outcomes, including coronary heart disease, subclinical disease, and peripheral artery disease, were pooled. Second, the analysis was limited to only men. Third, data from studies of diverse designs were combined. Fourth, heterogeneous risk estimates reported from the included studies were not transformed to a consistent comparison to allow meaningful interpretation of the findings.
With the ongoing debate on the potential value of total bilirubin levels in CVD risk prevention (ie, either as a causal therapeutic target or as a marker of risk prediction), 6, 14, 15 there is a requirement, therefore, for an adequately powered, comprehensive assessment of the association of baseline total bilirubin levels with risk of future first-ever CVD events in the general population using long-term observational evidence.
To help characterize and quantify more reliably the nature and magnitude of the association, we report a detailed assessment of the association of total bilirubin levels with risk of CVD from a large population-based sample of 7222 participants free from CVD at entry. In addition, we report the extent to which total bilirubin measurements could improve the prediction of first-onset CVD outcomes in general population settings when added to a conventional risk prediction model. Finally, to contextualize these findings, we report an updated meta-analysis of published prospective evidence on the associations of baseline levels of total bilirubin and risk of CVD in the general population.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Results From the PREVEND Cohort
Baseline Characteristics and Correlates of Total Bilirubin
In the Prevention of Renal and Vascular End-stage Disease (PREVEND) study, data were available for 7222 participants without a known history of CVD at baseline. Overall, the mean age of participants at baseline was 48 (SD, 12) years and 52% were women. Median (interquartile range) circulating total bilirubin level was 7 (4) μmol/L. Log e total bilirubin levels were weakly and inversely correlated with physical measures (body mass index, waist:hip ratio, and blood pressure), as well as several lipid and metabolic markers. Moderately strong correlations were observed for log e triglycerides (r=−0.25) and log e high-sensitivity C-reactive protein (r=−0.22). Baseline total bilirubin levels were higher by 23% in men when compared with that in women. The levels were lower by 6% in people with diabetes mellitus when compared with nondiabetics and by 13% in current smokers when compared with noncurrent smokers (Table 1) . Clinical and laboratory data of participants with and without incident CVD are shown in Appendix V in the online-only Data Supplement. Except for total bilirubin levels, there were significant differences in levels of risk markers between participants with and without incident CVD.
Circulating Total Bilirubin Levels and Risk of Incident CVD
During an average follow-up of 9.3 years (67 306 person-years at risk), 773 incident CVD events (annual rate 11.4/1000 person-years at risk; 95% confidence interval [CI], 10.6 to 12.2) were recorded. In analyses adjusted for established CVD risk factors (age, sex, smoking status, history of diabetes mellitus, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, and body mass index), there was a log-linear association between total bilirubin and CVD risk ( Figure 1 ). The age-and sex-adjusted hazard ratio per 1-SD change in log e total bilirubin was 0.82 (95% CI, 0.76 to 0.88; P<0.001), which was minimally attenuated to 0.89 (95% CI, 0.82 to 0.96; P=0.003) after further adjusting for established CVD risk factors. The results remained consistent after additionally adjusting for alcohol consumption, glucose, serum triglycerides, γ glutamyltransferase, and alanine aminotransferase 0.91 (95% CI, 0.83 to 0.98; P=0.015; Table 2 ). Hazard ratios did not vary importantly in analyses that excluded CVD outcomes recorded in the first 2 years of follow-up, participants with a history of diabetes mellitus at baseline, participants on regular lipid-lowering medication, or participants with potential Gilbert syndrome ( Table 3 ). The associations did not vary significantly by levels of several clinically relevant characteristics and other risk markers (P for interaction >0.10 for each), except for age that approached marginal significance (P=0.08). A significant log-linear inverse association was observed in men 0.88 (95% CI, 0.81 to 0.97) when compared with a nonsignificant association in women 0.90 (95% CI, 0.78 to 1.04; P for interaction=0.84; Figures 1 and 2). To put the strength of the association of total bilirubin levels with CVD risk into context, direct comparisons were made to associations of various CVD risk factors. The association of circulating total bilirubin with CVD risk was of comparable strength with high-density lipoprotein cholesterol and total cholesterol. Current smoking and systolic blood pressure seemed somewhat more strongly associated with CVD risk (Table 4 ). Whereas, there was a linear association of total bilirubin with coronary heart disease risk in analyses initially adjusted for age and sex, any association was confounded by established risk factors. There was no significant evidence of an association with stroke risk ( Figure 1 ; Table 3 ).
Circulating Total Bilirubin and CVD Risk Prediction
The addition of high-density lipoprotein cholesterol to a prognostic model for first cardiovascular events that included data on age, sex, smoking status, blood pressure, and total cholesterol increased the C-index by 0.0033 (0.0005 to 0.0061; P=0.02). The further addition of information on total bilirubin levels to this model increased the C-index by 0.0013 (−0.0004 to 0.0029; P=0.13; Appendix VI in the online-only Data Supplement), yielding a net reclassification index of 1.24% (−0.17% to 2.65%; P=0.09) for the predicted 10-year CVD risk categories. There were no differences in the C-index according to individual-level clinically relevant characteristics (Appendix VII in the online-only Data Supplement). There was no significant improvement in risk discrimination and reclassification when the model containing the Reynolds Risk Score components was used (Appendix VIII in the onlineonly Data Supplement).
Literature-Based Meta-Analyses
Literature Search, Characteristics, and Quality of Eligible Studies
Initial search identified 1482 potentially relevant citations. After screening and detailed assessment, 12 articles based on 11 unique population-based studies were included (Appendix IX and X in the online-only Data Supplement). Therefore, we meta-analyzed estimates from 12 studies (including the current study) involving a total of 173 325 unique participants ALT indicates Alanine aminotransferase; Apo A-I, apolipoprotein A-I; Apo B, apolipoprotein B; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; GGT, γ glutamyltransferase; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; SBP, systolic blood pressure; and WHR, waist:ratio.
*Pearson correlation coefficients between log e total bilirubin and the row variables. †Percentage change in total bilirubin levels per 1-SD increase in the row variable (or for categorical variables, the percentage difference in mean total bilirubin levels for the category vs the reference) adjusted for age and sex.
with 9378 incident CVD cases reporting on the association between total bilirubin and CVD risk. Detailed characteristics of these studies and quality assessment have been summarized in Appendix XI and XII in the online-only Data Supplement.
Total Bilirubin and CVD Risk in Pooled Analysis
The pooled relative risk (95% CI) for CVD per 1-SD higher total bilirubin level for studies that reported age-and sexadjusted analyses was 0.89 (0.83 to 0.96; P=0.001). The corresponding pooled relative risk in analyses typically adjusted for several established CVD risk factors was 0.93 (0.90 to 0.97; P<0.001; Figure 3 ). Exclusion of any single study at a time from the pooled analysis had minimal effect on the pooled relative risks. We found evidence of moderate heterogeneity between the contributing studies (I 2 =45%, 0%-72%; P=0.05), which was to some extent explained by fasting state of blood samples used for measurement of total bilirubin (P for meta-regression=0.008). A stronger inverse association was found for studies that used fasting samples of 0.89 (0.84 to 0.94) when compared with those that used nonfasting samples 0.97 (0.95 to 0.99). There were consistent associations across several study characteristics assessed (P for meta-regression >0.10; Appendix XIII in the online-only Data Supplement). The pooled corresponding fully adjusted estimates for coronary heart disease (8 studies; 4994 cases) and stroke end points (4 studies, 2641 cases) were 0.95 (0.92 to 0.99; P=0.018) and 0.93 (0.88 to 0.98; P=0.006), respectively (Appendix XIII and XIV in the online-only Data Supplement). There was some evidence of publication bias (Egger P=0.03; Appendix XV in the onlineonly Data Supplement), indicating that studies with less striking results were less likely to have been reported although we found no clear evidence of such selective reporting on overall Log total bilirubin concentration(µmol/l)
Females Males
Cardiovascular disease Figure 1 . Hazard ratios for incident cardiovascular disease, coronary heart disease, and stroke from multivariate-adjusted fractional polynomials. Hazard ratios were adjusted for age, sex, smoking status, history of diabetes mellitus, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, and body mass index. Note: the first category is the reference.
risk when studies were grouped by sample size (Appendix XIII in the online-only Data Supplement). Duval and Tweedie trimand-fill method resulted in no additional imputed studies.
Discussion
Our findings in the PREVEND cohort generally concur and further extend previous population-based cohort studies, providing several relevant findings that have not been previously addressed. In this population-based study of individuals without a history of CVD at baseline, there were generally modest inverse associations of total bilirubin levels with several cardiometabolic risk markers. This large-scale data also suggest that baseline circulating total bilirubin level is modestly, inversely, and log-linearly associated with first-ever CVD outcomes in the general population, which is in contrast to the nonlinear associations that have been reported 6, 16, 17 or suggested previously. 3, 18 The association was independent of several established risk factors. In addition, our results remained generally consistent across several clinically relevant subgroups and at different levels of risk factors, except for the suggestion of effect modification by age that was marked by a stronger association in individuals <50 years; however, in the context of multiple statistical tests for interaction conducted and the marginally significant P value, the results should be interpreted with caution and may require replication in additional studies. The associations were similar in analyses that excluded CVD outcomes recorded in the first 2 years of follow-up, participants with a history of diabetes mellitus at baseline, participants on regular statin medication, or participants with potential Gilbert syndrome. A strong inverse association was observed in men when compared with a nonsignificant association in women although there was no evidence of statistically significant effect modification by sex on the bilirubin-CVD association. Findings from assessments of improvements in measures of risk discrimination and reclassification indicate that total bilirubin provides no significant improvement in CVD risk prediction.
Pooled findings from the systematic meta-analysis of 12 studies reinforces the validity and generalizability of these new data, suggesting that a 2-fold increase in baseline circulating total bilirubin level is associated with ≈10% lower risk of CVD. Unlike the previous meta-analysis by Novotný and Vítek, 13 our current pooled analyses of 12 studies (of which only 3 included in the previous review were eligible) provide a more detailed assessment of the nature and magnitude of the association between circulating total bilirubin levels and risk of CVD (including coronary heart disease and stroke). In our updated review, the observed heterogeneity among the studies seemed to be explained, in part, by fasting state of blood samples used. There were stronger associations in studies that used fasting samples when compared with those that used nonfasting samples, which reflects observations that fasting increases circulating levels of total bilirubin. 19, 20 
Possible Explanations for Findings
Plausible biological mechanisms by which higher serum total bilirubin contributes to reduced CVD risk include its antioxidant actions 1, 21 (through inhibition of low-density lipoprotein oxidation), 22 anti-inflammatory effects, 23 antiatherogenic properties, 18 or more recently reported, pathways associated with vascular structure and reactivity. 24 Our findings of a significant inverse association of total bilirubin levels with CVD risk in men compared with a nonsignificant association in women are consistent with previous reports 3, 5 and may be attributable to a lower event rate in female participants. The findings of a graded, inverse, and independent association between total bilirubin levels and CVD risk are suggestive of causality, but it Table 3 is not possible to make causal inferences using observational epidemiological studies, as such data are limited by residual confounding and reverse causation. 25, 26 Randomized trials of interventions that modify (increase) bilirubin levels could inform whether bilirubin is causal in CVD. However, such available interventions, such as niacin, influence levels of lipid factors, making it difficult to disentangle any potential associations attributed to changes in bilirubin alone. 27 Integrative studies of genetic variants specifically related to bilirubin level may provide another route to help judge whether bilirubin could be directly causal in CVD (ie, Mendelian randomization analysis). 28 A common genetic variation (the rs6742078 variant) within the UGT1A1 gene has been found to be robustly associated with increased circulating levels of total bilirubin and has been used as an instrument for examining the causal effect of total bilirubin on disease outcomes. 20, 29 Using a Mendelian randomization approach using this variant as an instrumental variable, Stender et al 20 suggested a noncausal association between total bilirubin and CVD risk. The authors were, however, cautious in their conclusion and called for additional work to extend their results. Larger Mendelian randomization studies using the use of allele scores may be needed to rule out any causal relevance of total bilirubin to CVD risk. This approach will increase power and reduce the lack of specificity associated with single nucleotide polymorphisms. [30] [31] [32] Our findings may have several implications. Irrespective of whether addition of information on total bilirubin levels to Age at survey (years) <50 50-60 >60 conventional risk factors provides no improvement in CVD risk prediction, its use for CVD risk prevention has been proposed; 33 given that it is a simple, standardized, cost-effective, and scalable biomarker and may have a potential role in the cause of CVD. The overall evidence from this study supports the possibility that mildly elevated circulating total bilirubin levels might protect from CVD events in the general population. Novel therapeutic strategies (such as heme oxygenase-1 inducers and drugs that reduce hepatic glucuronidation activity or inhibit hepatocyte uptake) 34, 35 that cause mild-to-moderate elevations in circulating levels of bilirubin have been proposed as future tools for CVD prevention and treatment. 33 As reported by Targher 33 and Li et al, 36 given that markedly elevated bilirubin levels may exert toxic effects in certain situations 23, 37 and also increase the risk for CVD 38, 39 and mortality, 40 caution is still required.
. Hazard Ratios for Cardiovascular Disease With First 2 Years of Follow-up, Participants With History of Diabetes Mellitus, Participants on Regular Lipid-Lowering Medication, and Participants With Potential Gilbert Syndrome Excluded
Sex
Males Females
History of diabetes No Yes
Smoking status
Strengths and Limitations
Our study has several strengths and limitations to consider. Our study included analyses of primary data and a systematic synthesis of all available published prospective cohorts in a single comprehensive investigation. PREVEND participants were selected from a nationally representative sample with a high response rate and were prospectively followed up for an average period of 9 years. Participants were prospectively monitored using established databases for hospital admissions, supplemented with information on a comprehensive panel of lifestyle and biological markers that permitted us to control for potential confounders. Individuals with prevalent CVD at baseline were excluded from the analyses, which may more closely reflect causal associations, because it limits any possibilities of reverse-causation bias. The current study had enhanced power to examine the associations in greater detail. We also performed several sensitivity analyses such as excluding participants with a history of diabetes mellitus, CVD events in the first 2 years of follow-up, participants on regular statin medication, or participants with potential Gilbert syndrome, to avoid potential bias because of undiagnosed disease at baseline. Participants in the current study were suitable for risk prediction analysis (ie, prevalent CVD or diabetes mellitus were excluded at baseline and had complete measurements on risk factors used in standard risk prediction algorithms). Unlike the previous review, our meta-analysis only included studies that reported recruiting participants from approximately general populations and we presented standardized pooled risk estimates (ie, per SD change in baseline total bilirubin levels). We also conducted detailed analyses under a broader range of individual and study-level circumstances to explore the potential sources of heterogeneity. In the PREVEND cohort, because of the observational nature of data available, potential residual confounding caused by errors in risk marker measurements and other unmeasured confounders (such as thyroid hormones 41 Analyses are based on 7222 participants with 773 first-ever cardiovascular disease events. Hazard ratios were calculated per 1-SD increment in measured level or when compared with the relevant reference category. Where appropriate, hazard ratios were adjusted for age, sex, smoking status, history of diabetes mellitus, systolic blood pressure, total cholesterol, high-density lipoproteincholesterol, and body mass index. CI indicates confidence interval ; and PREVEND, Prevention of Renal and Vascular End-stage Disease.
adiponectin, which plays a crucial role in the heme oxygenase pathway) 42 cannot be entirely ruled out. The lack of fractionation of total bilirubin into indirect and direct fractions limited the ability to evaluate which bilirubin fraction was associated with cardiovascular risk. However, we have observed a strong correlation between total bilirubin and unconjugated bilirubin, as well as between total bilirubin and conjugated direct bilirubin in healthy subjects. 41 Finally, measurements of total bilirubin in the PREVEND study involved prolonged plasma storage (at −80°C), which might contribute to the weak association demonstrated in our analyses. The analyses, however, produced associations with CVD risk, which were similar to that of previous studies, many of which used fresh serum samples, arguing against underestimation because of sample degradation.
Conclusions
There is a modest log-linear inverse association between circulating total bilirubin levels and CVD risk, which is independent of several established risk factors. In adults without a known history of diabetes mellitus or CVD, adding total bilirubin to conventional CVD risk factors provides no significant improvement in CVD risk prediction.
